Agree on good science and poor execution.
any exec who can’t sell a product during a pandemic is NOT even worth discussing. He needs to go…simply not worth arguing against it
i didn’t buy into ADO 10 years ago for its RATs product. So I’m not devastated by this delay. But it’s the inability to execute a strategy during a pandemic where all the regulations and frameworks were relaxed
Ann: TGA Registration Update, page-382
-
- There are more pages in this discussion • 123 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
